ACHV$4.81
$4.7849
Chart
Performance
Key Stats
AI ACHV Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldAchieve Life Sciences (ACHV) is a late-stage pharmaceutical company focused on nicotine independence with cytisinicline. While the thematic focus on health and wellness is positive, fundamental and technical indicators suggest significant headwinds and uncertainty. Investors should exercise caution and monitor clinical trial progress and regulatory approvals.
Thematic
The company operates within the pharmaceutical and biotechnology sectors, focusing on developing treatments for addiction, specifically nicotine dependence. This aligns with growing global health awareness and demand for smoking cessation solutions, but competition and regulatory hurdles are significant.
Fundamental
Achieve Life Sciences (ACHV) exhibits weak financial fundamentals. The company has not generated revenue, has a history of substantial net losses, and is burning through cash, relying on financing. Its balance sheet shows increasing debt and decreasing cash reserves, presenting significant financial risk.
Technical
ACHV's technical indicators suggest a bearish short-to-medium term outlook. The stock is trading below key moving averages, and momentum indicators are mixed to negative. The RSI is in neutral territory, but recent performance indicates downward pressure.
| Factor | Score |
|---|---|
| Nicotine Addiction Treatment Market | 70 |
| Biopharmaceutical Innovation | 80 |
| Healthcare Policy & Regulation | 50 |
| Competition | 60 |
| Factor | Score |
|---|---|
| Valuation | 0 |
| Valuation | 0 |
| Profitability | 0 |
| Growth | 0 |
| Balance Sheet Health | 40 |
| Cash Flow | 10 |
| Financial Stability | 20 |
| Factor | Score |
|---|---|
| Trend Analysis | 20 |
| Momentum | 50 |
| Volume Confirmation | 40 |
| Support & Resistance | 30 |
| Short-term Performance | 60 |
| Short-term Performance | 10 |
AI Investing Checklist
Powered by LiveAIBullish Points (11)
Focused Business Model
Achieve Life Sciences, Inc. is a late-stage pharmaceutical company focused on developing and commercializing cytisinicline for nicotine independence. This specialization can lead to deep expertise and targeted market penetration.
Short-Term Positive Momentum
The stock has shown positive performance over the last 1 month (+20.18%) and 5 days (+1.13%), indicating recent investor interest or positive developments.
Bearish Points (12)
Negative Earnings and High P/E
The company has a negative EPS TTM of -1.35 and a P/E ratio of null, indicating a lack of current profitability. The TTM P/E of -3.5 in valuation summary further reinforces this. No P/S ratio data is available, suggesting minimal to no revenue.
No Revenue Reported
Across all valuation summaries (TTM, 2024, 2023, 2022, 2021) and growth/profitability reports, Total Revenue is consistently listed as 0, indicating the company is pre-revenue and solely reliant on funding.
Calendar
July 2020
31
Next Dividend Date
August 2025
7
Next Earnings Date
H: $-0.26
A: $-0.35
L: $-0.46
Profile
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
Seasonals
Price Target
16.71 USD
The 39 analysts offering 1 year price forecasts for ACHV have a max estimate of 30.00 and a min estimate of 10.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Major pharmaceutical company with a leading Alzheimer's disease drug (Donanemab, an antibody targeting amyloid beta), representing a direct competitor and a benchmark in the AD therapeutic space.
Weight: 92
Key biopharmaceutical company in Alzheimer's disease therapeutics, having co-developed Aducanumab (Aduhelm) and Lecanemab (Leqembi) with Eisai, both antibodies targeting amyloid beta. Direct competitor in the AD market.
Weight: 90
Japanese pharmaceutical company that co-developed Lecanemab (Leqembi) with Biogen for Alzheimer's disease, making them a significant direct competitor in the same therapeutic area as ACHV.
Weight: 88
Major global pharmaceutical company with a substantial neuroscience pipeline, including past and ongoing research in Alzheimer's disease (e.g., Gantenerumab, an amyloid-beta antibody), indicating a strong focus on similar neurodegenerative conditions.